| 产品名称 | Peptides EP12190_1 | BCR-ABL 926-934 (HLA-A*02:01) |
|---|---|
| 目录号 | EP12190_1 |
| 别名 | BCR-ABL 926-934 (HLA-A*02:01) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP12190_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP12190_1 | BCR-ABL 926-934 (HLA-A*02:01)
品名：BCR-ABL 926-934 (HLA-A*02:01)
货号：EP12190_1
规格：1 mg; 5 mg
品牌：Peptides.de
产品描述
In chronic myelogenous leukemia, a translocation occurs between chromosomes 9 and 22, which leads to a BCR-ABL fusion gene. This results in chimeric proteins.The nonapeptide BCR-ABL 926-934 (epitope ID 2187155) with the amino acid sequence SSKALQRPV from the junctional region of the BCR-ABLb3a2 molecule has been shown to be immunogenic. It could therefore be useful for developing a specific immunotherapy for patients with chronic myelogenous leukemia. BCR-ABL 926-934 binds to HLA-A2.1 molecules and triggers primary reactions of cytotoxic T lymphocytes in vitro.
| Protein | Human Bcr-abl 210 kD fusion protein |
| Species | Human |
| Application | Flow Cytometry |
| Indication | Cancer |
